Epigenomics, Qiagen Ink Colorectal Cancer Option Deal

The agreement enables Qiagen to develop a colorectal cancer blood test based on Epigenomics' mSept9 biomarker and certain DNA methylation analysis technologies.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories